Phase 3 Clinical Study of S-4661 in pediatric patients with meningitis and other bacterial infections
Phase 3
- Conditions
- (1) bacterial infections (Finibax indicatitons), (2) meningitis
- Registration Number
- JPRN-jRCT2080221492
- Lead Sponsor
- SHIONOGI & CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Hospitalized pediatrics from 28 days to less than 16 years with meningitis and other bacterial infections requiring intravenous antibiotic (carbapenem) therapy, etc.
Exclusion Criteria
Patients with a previous history of anaphylactic reactions or serious hypersensitivity to doripenem
Patients with serious hepatic impairment or patients with serious renal impairment
And et al.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method